Skip to content

midazolam with dexmedetomidine for ?extubation

Comparison of the effect of midazolam with dexmedetomidine before ?extubation on anesthesia emergence reactions in patients after lumbar disc ?surgery: a randomized clinical trial study

Status
Recruiting
Phases
Phase 3
Study type
Interventional
Source
IRCT
Registry ID
IRCT20210415050976N2
Enrollment
90
Registered
2021-05-25
Start date
2021-05-22
Completion date
Unknown
Last updated
2021-05-26

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Lumbar disc surgery. Spondylolysis, lumbar region

Interventions

Intervention 1: Intervention group 1: Patients in group 1 will receive midazolam 20 minutes before extubation at a dose of 20. mg per kg of body weight. Intervention 2: Intervention group 2: Patients

Sponsors

Jahrom University of Medical Sciences
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 65 Years

Inclusion criteria

Inclusion criteria: Candidates for lumbar disc surgery referred to Peymaniyeh Hospital in Jahrom Complete satisfaction to participate in the study No smoking and alcohol Lack of uncontrolled cardiovascular disease and diabetes and obesity No history of hypertension, no history of asthma and chronic obstructive pulmonary disease Age between 18 and 65 years

Exclusion criteria

Exclusion criteria: occurrence of symptoms indicating an airway problem Risk factor for aspiration Recent airway infection Bmi above 30

Design outcomes

Primary

MeasureTime frame
Vital signs. Timepoint: Before the extubation, 5 minutes after extubation, when entering recovery room, 5 and 10 minutes after recovery. Method of measurement: Monitoring device.

Secondary

MeasureTime frame
Occurrence of cough. Timepoint: During and after extubation. Method of measurement: Likert scale for measuring cough (no cough = 0, mild cough = 1, moderate cough = 2 and severe cough = 3).;Nausea and vomiting. Timepoint: During and after extubation. Method of measurement: Likert spectrum for measuring nausea (no nausea = 0, no nausea = 1 and no vomiting = 2).

Countries

Iran (Islamic Republic of)

Contacts

Public ContactNavid Kalani

Jahrom University of Medical Sciences

k.navid@juma.ac.ir+98 71 5433 6085

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026